| Literature DB >> 27716898 |
Melissa Frick1, Pierre Mouchacca1, Grégory Verdeil1, Yannick Hamon1, Cyrille Billaudeau1, Michel Buferne1, Mathieu Fallet1, Nathalie Auphan-Anezin1, Anne-Marie Schmitt-Verhulst1, Claude Boyer1.
Abstract
Cancer-germline genes in both humans and mice have been shown to encode antigens susceptible to targeting by cytotoxic CD8 T effector cells (CTL). We analysed the ability of CTL to kill different tumour cell lines expressing the same cancer-germline gene P1A (Trap1a). We previously demonstrated that CTL expressing a T-cell receptor specific for the P1A35-43 peptide associated with H-2Ld , although able to induce regression of P1A-expressing P815 mastocytoma cells, were much less effective against P1A-expressing melanoma cells. Here, we analysed parameters of the in vitro interaction between P1A-specific CTL and mastocytoma or melanoma cells expressing similar levels of the P1A gene and of surface H-2Ld . The mastocytoma cells were more sensitive to cytolysis than the melanoma cells in vitro. Analysis by video-microscopy of early events required for target cell killing showed that similar patterns of increase in cytoplasmic Ca2+ concentration ([Ca2+ ]i) were induced by both types of P1A-expressing tumour cells. However, the use of CTL expressing a fluorescent granzyme B (GZMB-Tom) showed a delay in the migration of cytotoxic granules to the tumour interaction site, as well as a partially deficient GZMB-Tom exocytosis in response to the melanoma cells. Among surface molecules possibly affecting tumour-CTL interactions, the mastocytoma cells were found to express intercellular adhesion molecule-1, the ligand for LFA-1, which was not detected on the melanoma cells.Entities:
Keywords: cytolytic T lymphocyte; fluorescent granzyme B; melanoma; tumour
Mesh:
Substances:
Year: 2016 PMID: 27716898 PMCID: PMC5214755 DOI: 10.1111/imm.12679
Source DB: PubMed Journal: Immunology ISSN: 0019-2805 Impact factor: 7.397